ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT00509769

Public ClinicalTrials.gov record NCT00509769. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Single-arm, Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy

Study identification

NCT ID
NCT00509769
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Genentech, Inc.
Industry
Enrollment
112 participants

Conditions and interventions

Interventions

  • Trastuzumab emtansine [Kadcyla] Drug

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2007
Primary completion
Dec 31, 2008
Completion
May 31, 2009
Last update posted
Apr 1, 2013

2007 – 2009

United States locations

U.S. sites
40
U.S. states
18
U.S. cities
37
Facility City State ZIP Site status
Little Rock Hem Onc Assoc Little Rock Arkansas 72205
Rocky Mountain Cancer Center Denver Colorado 80220
Washington Cancer Institute Washington D.C. District of Columbia 20010
Lynn Cancer Institute - West Boca Raton Florida 33428
Florida Cancer Care Davie Florida 33328
Mayo Clinic Jacksonville Florida 32224
Hem/Onc Assoc - Treasure Coast Port Saint Lucie Florida 34952
Gulfcoast Oncology Associates St. Petersburg Florida 33705
Bay Area Oncology Tampa Florida 33607
Northwest Georgia Onc Ctrs PC Marietta Georgia 30060
John McClean, M.D. - Private P Galesburg Illinois 61401
Cedar Valley Med Specialists Waterloo Iowa 50702
Kentuckiana Cancer Institute Louisville Kentucky 40202
Minnesota Oncology Hematology, Minneapolis Minnesota 55404
Missouri Cancer Associates Columbia Missouri 65201
Kansas City Cancer Center, LLC Lee's Summit Missouri 64064
St. Louis Cancer & Breast Inst St Louis Missouri 63141
St. Barnabas Health Care Sys Livingston New Jersey 07039
New York Oncology Hematology Albany New York 12206
Eastchester Center/Cancer Care The Bronx New York 10469
Carolinas Hem-Oncology Assoc Charlotte North Carolina 28203
Raleigh Hemotology & Oncology Raleigh North Carolina 27607
Midwestern Regional Med Center Eugene Oregon 97401-8122
Texas Oncology Cancer Center Austin Texas 78731
Texas Oncology, P.A. Bedford Texas 76022
Cancer Specialists of South Te Corpus Christi Texas 78412
US Oncology Research, Inc. Dallas Texas 75204
USO Dallas Texas 75230-2510
Texas Oncology, P.A. Dallas Texas 75231-4400
Sammons Cancer Center Dallas Texas 75246
El Paso Cancer Treatment Ctr El Paso Texas 79915
Texas Oncology PA Fort Worth Texas 76104
Texas Oncology, P.A. Houston Texas 77024-2305
US Oncology Midland Texas 79701
USO - Tyler Cancer Ctr Tyler Texas 75702
Waco Cancer Care & Research Ce Waco Texas 76712
Northern Utah Associates Ogden Utah 84403
Fairfax N Virginia Hem/Onc PC Fairfax Virginia 22031
Northwest Medical Specialties Tacoma Washington 98405
Northwest Cancer Specialists Vancouver Washington 98684

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00509769, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2013 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00509769 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →